GO:0043568 positive regulation of insulin-like growth factor receptor signaling pathway: Signaling Amplification, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043568 describes any process that increases the frequency, rate or extent of insulin-like growth factor receptor (IGF1R) signaling, a core growth and survival pathway.
• Positive regulation of IGF1R signaling is driven by ligand availability (IGF1, IGF2), receptor abundance, and downstream adaptor/scaffold proteins that amplify signal transduction.
• The pathway is frequently hyperactivated in breast, prostate, and other cancers, where it promotes proliferation, stemness, and therapy resistance.
• Metabolic states such as obesity and metabolic syndrome alter IGF/IGFBP balance, indirectly tuning IGF1R signaling intensity.
• Key experimental approaches include CRISPR knockout/knock-in of IGF1R, IGF1, IGF2, IRS1/2, and negative regulators, combined with phospho-proteomics and transcriptomics.
• EDITGENE provides end-to-end CRISPR services (KO, point mutation, knock-in, overexpression, library screening, bioinformatics) to dissect positive regulation of IGF1R signaling in any cell model.
Description
The Gene Ontology term GO:0043568, positive regulation of insulin-like growth factor receptor signaling pathway, captures all biological processes that enhance the activity of the insulin-like growth factor receptor (IGF1R) signaling cascade. IGF1R is a receptor tyrosine kinase activated by IGF1 and IGF2, and its signaling is essential for normal growth, development, and tissue homeostasis. When this pathway is positively regulated, cells increase glucose uptake, protein synthesis, proliferation, and survival, making it a central node in both physiology and disease. Understanding how this positive regulation occurs is critical because excessive IGF1R signaling is a hallmark of many cancers and metabolic disorders. Research into GO:0043568 spans ligand bioavailability, receptor expression, post-translational modifications, and downstream adaptor proteins that sustain signal duration and amplitude. For example, diet-derived metabolites and adipocyte-derived factors can reprogram hepatocytes or tumor cells to modulate IGF1R signaling and immune responses. In breast cancer, immune and growth factor signaling pathways, including IGF1R, are associated with pathologic complete response to anti-IGF1R regimens, highlighting the clinical relevance of positive regulation. Similarly, in prostate cancer, exosomes enriched with c-Src, IGF1R, and focal adhesion kinase can propagate oncogenic signaling. This article provides a research-grade overview of GO:0043568, covering its definition, molecular players, disease links, and state-of-the-art methods to study it. By integrating QuickGO annotations with verified PubMed literature, we aim to equip researchers with a clear framework for investigating positive regulation of IGF1R signaling and for designing CRISPR-based experiments to test causality.
positive regulation of insulin-like growth factor receptor signaling pathway At A Glance
| GO ID | GO:0043568 |
|---|---|
| GO term | positive regulation of insulin-like growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | activation of insulin-like growth factor receptor signaling pathway; positive regulation of IGF receptor signaling pathway; stimulation of insulin-like growth factor receptor signaling pathway; upregulation of insulin-like growth factor receptor signaling pathway |
| Major function | Enhances IGF1R signaling to promote cell growth, survival, and metabolic regulation |
| Related ligands | IGF1, IGF2, insulin (with lower affinity) |
| Key receptor | IGF1R (insulin-like growth factor 1 receptor) |
| Downstream effectors | IRS1/2, PI3K/AKT, MAPK/ERK |
| Disease relevance | Cancer, metabolic syndrome, endocrine resistance |
What Is GO:0043568?
GO:0043568 is a biological process term defined as any process that increases the frequency, rate or extent of insulin-like growth factor receptor signaling. In other words, it encompasses molecular events that amplify or prolong the signal initiated by IGF1R upon ligand binding, leading to enhanced downstream cellular responses such as proliferation, survival, and metabolism.
Why Is positive regulation of insulin-like growth factor receptor signaling pathway Important in Cell Biology?
Positive regulation of IGF1R signaling is fundamental to normal growth and tissue repair, but its dysregulation drives cancer progression, metabolic disease, and therapy resistance. Because IGF1R signaling integrates nutrient availability, hormonal cues, and immune cell function, understanding its positive regulation offers therapeutic opportunities across oncology and metabolic disorders.
• Promotes cancer cell proliferation and survival in breast, prostate, and other malignancies.
• Supports cancer stem cell maintenance and self-renewal.
• Mediates endocrine resistance in breast cancer via adipocyte-tumor crosstalk.
• Links metabolic syndrome and obesity to altered IGF/IGFBP balance.
• Modulates T cell exhaustion and antitumor immunity through hepatocyte reprogramming.
• Contributes to aging and senescence through positive-feedback growth signaling.
• Enables exosomal transfer of oncogenic signaling components in prostate cancer.
• Serves as a biomarker for pathologic complete response to anti-IGF1R therapy.
• Provides targets for CRISPR-based functional genomics in growth factor signaling.
• Offers a paradigm for studying ligand-receptor-adaptor amplification loops.
What Happens During positive regulation of insulin-like growth factor receptor signaling pathway?
Ligand Availability and Receptor Activation
In simple terms: More ligand or more receptor means a stronger signal.
Positive regulation often begins with increased bioavailability of IGF1 or IGF2, or with upregulation of IGF1R at the cell surface. Ligand binding induces receptor autophosphorylation and activation of downstream cascades. In metabolic syndrome, altered IGF/IGFBP ratios can increase free IGF1, thereby enhancing receptor activation. Adipocyte-derived factors can also stimulate IGF1 production in tumor cells, creating a positive feedback loop.
Adaptor Protein Recruitment and Signal Amplification
In simple terms: Scaffold proteins keep the signal going and make it stronger.
Upon activation, IGF1R recruits adaptor proteins such as IRS1 and IRS2, which amplify signaling through PI3K/AKT and MAPK/ERK pathways. Positive regulation can occur via increased expression or reduced degradation of these adaptors. For example, ARMH4 maintains a positive-feedback growth signaling circuit that accelerates aging, involving IGF1R pathway components. Similarly, c-Src and focal adhesion kinase are enriched in prostate cancer exosomes and can potentiate IGF1R signaling.
Post-Translational Modifications and Feedback Loops
In simple terms: Chemical tags on proteins can turn the signal up or keep it on longer.
Phosphorylation, ubiquitination, and acetylation of IGF1R or its substrates can enhance or sustain signaling. Positive regulation may involve inhibition of negative regulators such as phosphatases (e.g., PTEN, PTP1B) or E3 ligases that normally degrade IGF1R. In breast cancer, immune and growth factor signaling pathways, including IGF1R, are associated with response to anti-IGF1R therapy, suggesting that feedback loops influence clinical outcomes.
Crosstalk with Metabolic and Immune Pathways
In simple terms: IGF1R signaling talks to other pathways to boost its effects.
Positive regulation of IGF1R signaling is intertwined with metabolic and immune signaling. Diet-derived galactose reprograms hepatocytes to prevent T cell exhaustion and elicit antitumor immunity, partly through growth factor signaling. In metabolic syndrome, IGF/IGFBP dysregulation links systemic metabolism to IGF1R activity. Adipocyte-tumor crosstalk via the IGF-1/TXNIP axis promotes malignancy and endocrine resistance, illustrating how microenvironmental signals positively regulate IGF1R signaling.
Downstream Cellular Outcomes
In simple terms: The boosted signal changes how cells grow, survive, and behave.
Enhanced IGF1R signaling leads to increased glucose uptake, protein synthesis, proliferation, and survival. In cancer stem cells, it promotes self-renewal and therapy resistance. In aging, sustained positive feedback can drive senescence and tissue dysfunction. These outcomes underscore why positive regulation of this pathway is a key research focus.
Key Genes Involved in GO:0043568 positive regulation of insulin-like growth factor receptor signaling pathway
The following genes and proteins are central to the positive regulation of IGF1R signaling, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IGF1 | Ligand that activates IGF1R | Target for modulating pathway activity in cancer and metabolism |
| IGF2 | Ligand with high affinity for IGF1R | Implicated in developmental and oncogenic signaling |
| IGF1R | Receptor tyrosine kinase | Central node; CRISPR KO/knock-in to study signaling |
| IRS1 | Adaptor protein downstream of IGF1R | Amplifies PI3K/AKT signaling; knockout reduces pathway output |
| IRS2 | Adaptor protein downstream of IGF1R | Modulates metabolic and survival signals |
| PIK3CA | Catalytic subunit of PI3K | Mutations enhance downstream signaling |
| AKT1 | Serine/threonine kinase | Key effector of IGF1R-mediated survival |
| MAPK1 | ERK2, downstream kinase | Mediates proliferative signals |
| IGFBP3 | Binding protein that sequesters IGFs | Negative regulator; its loss increases free IGF |
| IGFBP1 | Binding protein | Modulates IGF bioavailability in metabolic syndrome |
| TXNIP | Thioredoxin-interacting protein | Mediates adipocyte-tumor crosstalk via IGF-1 |
| SRC | Non-receptor tyrosine kinase | Enriched in exosomes; potentiates IGF1R signaling |
| PTK2 | Focal adhesion kinase | Co-enriched with IGF1R in exosomes |
| GRK2 | G-protein-coupled receptor kinase | Modulates receptor trafficking and signaling |
| ARMH4 | Armadillo-like protein | Maintains positive-feedback growth signaling in aging |
| GALM | Galactose mutarotase | Links diet-derived galactose to hepatocyte reprogramming |
How Is positive regulation of insulin-like growth factor receptor signaling pathway Regulated?
Positive regulation of IGF1R signaling is controlled at multiple levels. Ligand availability is regulated by IGFBPs, which sequester IGF1/IGF2 and prevent receptor activation. Receptor abundance is controlled by transcription, endocytosis, and degradation. Negative feedback loops involving phosphatases (e.g., PTEN) and E3 ligases normally restrain signaling; their inhibition enhances pathway output. Metabolic cues such as insulin and glucose can modulate IGF1R activity, and adipocyte-derived factors like TXNIP influence ligand production. In aging, ARMH4 sustains a positive-feedback circuit that amplifies growth signaling. These regulatory layers provide multiple entry points for experimental manipulation.
positive regulation of insulin-like growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IGF1R | Breast cancer, prostate cancer | CRISPR knockout in MCF-7 or PC-3 cells |
| TXNIP | Breast cancer endocrine resistance | Knockdown/overexpression in adipocyte-tumor co-cultures |
| IGFBP3 | Metabolic syndrome | CRISPR knockout in hepatocytes or adipocytes |
| ARMH4 | Aging | Overexpression or knockout in fibroblasts |
| SRC | Prostate cancer exosomal signaling | Point mutation (kinase-dead) in prostate cancer cells |
Breast Cancer and Endocrine Resistance
IGF1R signaling is frequently hyperactivated in breast cancer, promoting proliferation and survival. Positive regulation via adipocyte-tumor crosstalk through the IGF-1/TXNIP axis drives malignancy and endocrine resistance. Immune and growth factor signaling pathways, including IGF1R, are associated with pathologic complete response to anti-IGF1R regimens, suggesting that pathway activity predicts therapeutic outcome.
Prostate Cancer and Exosomal Signaling
In prostate cancer, exosomes enriched with c-Src, IGF1R, GRK2, and focal adhesion kinase propagate oncogenic signaling to recipient cells, effectively spreading positive regulation of IGF1R signaling. This mechanism may contribute to tumor progression and therapy resistance.
Metabolic Syndrome and Obesity
Metabolic syndrome is associated with altered IGF/IGFBP regulation, leading to increased free IGF1 and enhanced IGF1R signaling. Obesity-related adipocyte signals can further stimulate IGF1 production in tumors, linking metabolic dysfunction to cancer risk.
Aging and Immune Regulation
ARMH4 accelerates aging by maintaining a positive-feedback growth signaling circuit that includes IGF1R pathway components. Diet-derived galactose reprograms hepatocytes to prevent T cell exhaustion and elicit antitumor immunity, partly through growth factor signaling. These findings link positive regulation of IGF1R signaling to aging and immune surveillance.
From positive regulation of insulin-like growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IGF1R knockout reduce tumor growth? | CRISPR knockout in cancer cell lines (e.g., MCF-7, PC-3) |
| Does a specific point mutation in IRS1 affect pathway amplification? | CRISPR point mutation knock-in in HEK293 or cancer cells |
| Can overexpression of IGF1 enhance T cell exhaustion? | CRISPR overexpression in hepatocytes or co-culture systems |
| Does tagged IGF1R track receptor trafficking? | Knock-in of fluorescent tag (e.g., GFP) at IGF1R locus |
| Does ARMH4 knockout delay aging phenotypes? | CRISPR knockout in primary fibroblasts |
| Does TXNIP knockdown reverse endocrine resistance? | CRISPR knockout in breast cancer cells |
How to Study the positive regulation of insulin-like growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-proteomics | Phosphorylation of IGF1R, IRS1, AKT, ERK | Quantify pathway activation after CRISPR KO |
| RNA-seq | Transcript levels of IGF1, IGF2, IGF1R, IGFBPs | Identify feedback loops and crosstalk |
| Exosome isolation | Protein cargo (IGF1R, c-Src, FAK) | Study intercellular signaling |
| Co-culture assays | Cell proliferation, survival, immune exhaustion | Model microenvironmental regulation |
| CRISPR knockout | Gene function loss | Test causality of candidate regulators |
| CRISPR knock-in | Point mutations or tags | Study specific residues or track receptor |
| Overexpression | Gain-of-function | Enhance pathway activity |
| Bioinformatics | Pathway enrichment, network analysis | Integrate multi-omics data |
Phospho-Proteomics and Signaling Profiling
Phospho-proteomics can quantify changes in IGF1R, IRS1, AKT, and ERK phosphorylation upon genetic or pharmacological perturbation. This method reveals how positive regulation alters signal amplitude and duration.
Transcriptomics and RNA-seq
RNA-seq identifies transcriptional changes in IGF1, IGF2, IGF1R, IGFBPs, and downstream targets following CRISPR editing. It can uncover feedback loops and crosstalk with metabolic or immune pathways.
Exosome Isolation and Characterization
Exosomes can be isolated from conditioned media and analyzed for IGF1R, c-Src, and focal adhesion kinase content, as shown in prostate cancer models. This method studies intercellular propagation of positive regulation.
Co-Culture and Organoid Models
Adipocyte-tumor co-cultures and hepatocyte-immune co-cultures model microenvironmental positive regulation of IGF1R signaling. Organoids derived from patient tumors can test personalized responses to IGF1R inhibition.
How CRISPR Can Be Used to Study GO:0043568 positive regulation of insulin-like growth factor receptor signaling pathway
Knockout
CRISPR knockout of IGF1R, IRS1, or ARMH4 can abolish or reduce positive regulation of IGF1R signaling, revealing essential components. Knockout of negative regulators like IGFBP3 can enhance pathway activity.
Point Mutation
Point mutations in IGF1R kinase domain or IRS1 phosphorylation sites can dissect specific signaling events. For example, kinase-dead IGF1R prevents autophosphorylation and downstream activation.
Knock-in
Knock-in of fluorescent tags (e.g., GFP) at the IGF1R locus enables real-time tracking of receptor trafficking and localization. Knock-in of patient-derived mutations can model disease-associated variants.
Overexpression
CRISPR overexpression of IGF1 or IGF2 can boost ligand availability and enhance IGF1R signaling, mimicking pathological states such as cancer or metabolic syndrome.
How EDITGENE Supports positive regulation of insulin-like growth factor receptor signaling pathway Research
Researchers studying positive regulation of insulin-like growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway amplification, and which domains or residues mediate its effects. EDITGENE provides the full spectrum of CRISPR cell model services to answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of insulin-like growth factor receptor signaling pathway research.
Frequently Asked Questions About positive regulation of insulin-like growth factor receptor signaling pathway
What is GO:0043568?
GO:0043568 is the Gene Ontology term for positive regulation of insulin-like growth factor receptor signaling pathway, describing any process that increases the frequency, rate or extent of IGF1R signaling.
What genes are involved in positive regulation of IGF1R signaling?
Key genes include IGF1, IGF2, IGF1R, IRS1, IRS2, PIK3CA, AKT1, MAPK1, IGFBP3, TXNIP, SRC, PTK2, and ARMH4.
How is IGF1R signaling positively regulated?
It is positively regulated by increased ligand availability, receptor upregulation, adaptor protein recruitment, post-translational modifications, and crosstalk with metabolic and immune pathways.
Why is positive regulation of IGF1R signaling important in cancer?
Hyperactivation of IGF1R signaling promotes proliferation, survival, stemness, and therapy resistance in breast, prostate, and other cancers.
What diseases are associated with IGF1R signaling?
Breast cancer, prostate cancer, metabolic syndrome, endocrine resistance, and aging-related phenotypes are linked to altered IGF1R signaling.
How can CRISPR be used to study IGF1R signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models can test the causal role of specific genes and residues in IGF1R signaling.
What methods measure IGF1R pathway activity?
Phospho-proteomics, RNA-seq, exosome isolation, co-culture assays, and bioinformatics are commonly used.
What is the role of IGFBP3 in IGF1R signaling?
IGFBP3 binds IGF1 and IGF2, reducing their availability to IGF1R and thus negatively regulating the pathway; its loss can enhance signaling.
How does metabolic syndrome affect IGF1R signaling?
Metabolic syndrome alters IGF/IGFBP regulation, increasing free IGF1 and enhancing IGF1R activation.
Can EDITGENE help with CRISPR models for IGF1R signaling?
Yes, EDITGENE offers knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for IGF1R pathway research.
Conclusion
GO:0043568, positive regulation of insulin-like growth factor receptor signaling pathway, is a critical biological process that amplifies growth, survival, and metabolic signals. Its dysregulation contributes to cancer, metabolic syndrome, and aging, making it a prime target for therapeutic intervention and functional genomics. By leveraging CRISPR technologies and multi-omics methods, researchers can dissect the molecular players and design targeted strategies to modulate this pathway. EDITGENE stands ready to support these efforts with comprehensive cell model services.
References
- 1. Du X et al.. 2025. Diet-derived galactose reprograms hepatocytes to prevent T cell exhaustion and elicit antitumour immunity.. Nat Cell Biol 27(8):1357-1366 PMID: 40781141
- 2. Fang Y et al.. 2025. ARMH4 accelerates aging by maintaining a positive-feedback growth signaling circuit.. Nat Commun 17(1):812 PMID: 41390521
- 3. Yee D. 2018. Anti-insulin-like growth factor therapy in breast cancer.. J Mol Endocrinol 61(1):T61-T68 PMID: 29378771
- 4. Petricoin EF et al.. 2025. Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.. Clin Cancer Res 31(20):4361-4371 PMID: 40905691
- 5. Malaguarnera R et al.. 2014. The emerging role of insulin and insulin-like growth factor signaling in cancer stem cells.. Front Endocrinol (Lausanne) 5:10 PMID: 24550888
- 6. Pouriamehr S et al.. 2019. Investigation of insulin-like growth factors/insulin-like growth factor binding proteins regulation in metabolic syndrome patients.. BMC Res Notes 12(1):653 PMID: 31601230
- 7. Caruso A et al.. 2025. Adipocyte/Tumor cell crosstalk via IGF-1/TXNIP axis promotes malignancy and endocrine resistance in breast cancer.. Cell Commun Signal 23(1):262 PMID: 40462107
- 8. DeRita RM et al.. 2017. c-Src, Insulin-Like Growth Factor I Receptor, G-Protein-Coupled Receptor Kinases and Focal Adhesion Kinase are Enriched Into Prostate Cancer Cell Exosomes.. J Cell Biochem 118(1):66-73 PMID: 27232975
